Beyond Medical Technologies Inc (DOCT) AI Stock Analysis

• Market Cap: C$1.11M
• Dividend Yield: N/A
• Average Volume (3M): 5.78K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.31
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: CA
• Employees: N/A
• Sector: Industrials
• Sector Strength: 64
• Industry: Industrial - Pollution & Treatment Controls
• EPS (TTM): -0.05
• Shares Outstanding: 7,913,975
• 10 Day Avg. Volume: 12,243
• 30 Day Avg. Volume: 5,776
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): 11.10
• P/FCF Ratio: 11.10
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

The overall stock score for Beyond Medical Technologies Inc is significantly impacted by its critical financial health, characterized by zero revenue and negative profitability. While technical indicators show short-term positive momentum, the overbought conditions and poor valuation metrics suggest caution. Immediate strategic changes are necessary for financial recovery and sustainable growth.

Beyond Medical Technologies Inc Business Overview & Revenue Model

Company Description

Beyond Medical Technologies Inc (DOCT) is a healthcare technology company specializing in innovative medical solutions and devices. The company operates in the biotechnology and medical device sectors, focusing on the development and distribution of products that enhance patient care and streamline healthcare processes. Its core offerings include advanced diagnostic tools, telemedicine platforms, and wearable health monitoring devices.

How the Company Makes Money

Beyond Medical Technologies Inc generates revenue through the sale of its proprietary medical devices and technology solutions to healthcare providers, hospitals, and clinics. The company also monetizes its telemedicine platforms through subscription models and partnerships with healthcare institutions. Additionally, Beyond Medical Technologies Inc engages in strategic collaborations with pharmaceutical companies and research institutions to co-develop and license new technologies, contributing to its revenue streams.

Beyond Medical Technologies Inc Financial Statement Overview

Summary

Beyond Medical Technologies Inc faces severe financial challenges with zero revenue, negative profit margins, and high leverage risks. The financial statements indicate a critical need for strategic restructuring or pivoting to achieve financial stability and operational viability.

Income Statement

Beyond Medical Technologies Inc has consistently reported zero revenue in recent periods, which is a significant concern. The company shows a downward trend in profitability with negative EBIT and net income, indicating ongoing operational challenges. The lack of revenue growth and negative profit margins highlight severe difficulties in achieving sustainable operations.

Balance Sheet

The balance sheet reveals high leverage, with a negative stockholders' equity indicating significant liabilities exceeding assets. The debt-to-equity ratio is incalculable due to negative equity, which is a critical risk factor. The equity ratio is also concerning, showing negative equity relative to assets, highlighting financial instability and potential solvency issues.

Cash Flow

Cash flow analysis reveals negative operating and free cash flows, indicating that the company is not generating sufficient cash from its operations to sustain its activities. The operating cash flow to net income ratio is negative due to continuous losses, underscoring financial distress. The inflow from financing activities suggests reliance on external funding to maintain liquidity.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
0.00	0.00	0.00	943.42K	208.66K	0.00
	Gross Profit
0.00	0.00	0.00	-250.49K	24.68K	-120.27K
	EBIT
-503.44K	-514.04K	-838.94K	-2.46M	2.38M	-2.80M
	EBITDA
-223.17K	-37.96K	-773.19K	-1.34M	-6.38M	-5.25M
	Net Income Common Stockholders
-398.83K	-595.96K	-1.40M	-2.53M	-10.97M	-7.93M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
6.18M	64.14K	536.75K	1.43M	624.21K	3.25M
	Total Assets
8.50M	95.64K	608.18K	1.95M	1.84M	3.84M
	Total Debt
0.00	30.00K	0.00	85.09K	165.01K	230.96K
	Net Debt
-3.08M	-34.14K	-536.75K	-1.35M	-459.20K	-2.55M
	Total Liabilities
284.09K	430.35K	346.94K	413.28K	361.85K	305.74K
	Stockholders Equity
8.22M	-334.72K	261.25K	1.54M	1.48M	3.54M
Cash Flow		Free Cash Flow
-116.08K	-527.04K	-894.01K	-1.47M	-2.07M	-2.43M
	Operating Cash Flow
-116.08K	-527.04K	-894.01K	-1.40M	-1.83M	-2.40M
	Investing Cash Flow
0.00	0.00	0.00	-467.99K	-260.27K	1.82M
	Financing Cash Flow
60.00K	30.00K	0.00	2.67M	-65.96K	281.03K

Beyond Medical Technologies Inc Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.14
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:DOCT, the sentiment is Positive. The current price of 0.14 is above the 20-day moving average (MA) of 0.11, above the 50-day MA of 0.11, and above the 200-day MA of 0.05, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 55.78 is Neutral, neither overbought nor oversold. The STOCH value of 81.82 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:DOCT.

Beyond Medical Technologies Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	62 Neutral	$7.16B	12.21	3.05%	3.43%	3.62%	-14.48%
NEO	61 Neutral	C$330.41M	―	-3.15%	5.06%	-15.41%	-69.47%
PHA	48 Neutral	C$3.33M	―	-160.58%	―	44.96%	-827.30%
MDNA	42 Neutral	C$72.74M	―	-149.09%	―	―	-67.03%
DOCT	34 Underperform	C$1.11M	―	74.38%	―	―	―